Apathy in Dementia Methylphenidate Trial 2 (ADMET2)

What is the purpose of this trial?

Visit the Alzheimer's Disease Research Unit (ADRU) here.

Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) is a Phase III, placebo-controlled, masked, 6 month, 10-center randomized clinical trial sponsored by National Institutes of Aging involving 200 participants with Alzheimer's disease (AD). ADMET 2 is designed to examine the efficacy and safety of methylphenidate as treatment for clinically significant apathy in AD participants. ADMET 2 will enroll participants from real world settings such as outpatient, nursing home, and assisted living facilities and will examine the effects of methylphenidate on apathy and cognition. ADMET 2 will also conduct careful safety monitoring.

Participation Guidelines

Gender: Both

Johns Hopkins University

Dates: 10/09/2015 - 08/31/2019

Last Updated: 02/22/2018

Study HIC#: 1503015481

Get Involved

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Christopher H Van Dyck

Principal Investigator